45 to 64
Ro Offers Eli Lilly's Foundayo, the Newest GLP-1 Innovation Foundayo gives patients a new once daily pill option and expands Ros comprehensive weight loss formulary April 9, 2026 Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Companys newest oral GLP-1 innovation on the Ro platform, adding to Ros already comprehensive formulary of FDA-approved GLP-1s
Counter to this attitude was the emergence of the body positivity movement in the 2010s that sought to promote self-acceptance, celebrate body shape diversity, and prioritize metabolic health, challenging the use of BMI or weight as sole indicators of health without considering the broader context (Gailey, 2022
PloS One 9 (3), e90891
This can be achieved through various methods such as sonication, freeze-thaw cycles, enzymatic digestion (e.g., lysozyme treatment), or mechanical disruption (e.g., French press)